A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies (NCT06507306)
A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB198 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
Who can join: Review the eligibility criteria below.
Location: Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
- Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona - — Orlando, Florida
- Florida Cancer Specialists - Sarasota — Sarasota, Florida
- Henry Ford Health System — Detroit, Michigan
- David H. Koch Center for Cancer Center at Memorial Sloan Kettering Cancer Center — Long Island City, New York
- The Lindner Center for Research and Education at The Christ Hospital — Cincinnati, Ohio
- Sarah Cannon and HCA Research Institute — Nashville, Tennessee
- New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
- New Experimental Therapeutics of Virginia - NEXT Oncology — Fairfax, Virginia
- Institut Paoli-Calmettes — Marseille, Bouches-du-Rhône
- Institut de Cancerologie de l'Ouest - site St-Herblain — Saint-Herblain, Loire-Atlantique
- CHU Bordeaux - Hopital Saint-Andre — Bordeaux, Nouvelle-Aquitane
- IUCT-Oncopole — Toulouse, Occitaine
- CHU de Nantes - Hopital Nord Laennec — Nantes, Pays de la Loire Region
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore — Rome, Lazio
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" — Naples,
- Hospital Universitari Quiron Dexeus Barcelona — Barcelona, Catalonia
- Hospital Universitario Vall d'Hebron — Barcelona, Catalonia
- New Experimental Therapeutics (NEXT) Oncology Barcelona — Barcelona,
- South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos — Barcelona,
- Hospital Universitario Ramon y Cajal — Madrid,
- South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC — Madrid,
- New Experimental Therapeutics (NEXT) Oncology Madrid - Hospital Quironsalud Madrid — Madrid,
- South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz — Madrid,
- Hospital Quirónsalud Málaga — Málaga,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor, Adult
- A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Sarasota, Florida
- First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Los Angeles, California
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial — Scottsdale, Arizona
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression — Gilbert, Arizona
Explore by condition: All Solid Tumor, Adult clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.